Adverse reactions of Tofacitinib

Most common adverse reactions are:  

• Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: Reported during the first 3 months in rheumatoid arthritis placebo-controlled clinical trials and occurring in ≥2% of patients treated  with Tofacitinib monotherapy or in combination with DMARDs: upper  respiratory tract infection, nasopharyngitis, diarrhea, and headache.

• Ulcerative Colitis: Reported in ≥5% of patients treated with either 5 mg or 10 mg twice daily of Tofacitinib and ≥1% greater than reported in patients receiving placebo in either the induction or maintenance clinical trials:  nasopharyngitis, elevated cholesterol levels, headache, upper respiratory tract infection, increased blood creatine phosphokinase, rash, diarrhea,  and herpes zoster.

• Polyarticular Course Juvenile Idiopathic Arthritis: Consistent with  common adverse reactions reported in adult rheumatoid arthritis patients.

from FDA，2024.09